The first commercial use of a gadolinium-based contrast agent
in the UK was in 1988 and they have been part of clinical routine ever since.
Gadolinium-based contrast agent
toxicity: a review of known and proposed mechanisms.
Gadolinium-based contrast agents
, when given to patients with renal disease, have been associated with a rare, potentially fatal, scleroderma-like skin disease called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy.
According to a study published in August 2006 in the Journal of the American Society of Nephrology, 13 patients with severe renal disease developed NSF between two and 75 days after receiving Omniscan, a gadolinium-based contrast agent
manufactured by GE Healthcare.
It recommends that these agents be used only if absolutely necessary with prompt dialysis following the test in order to remove the circulating gadolinium-based contrast agent
It is usually done with gadolinium-based contrast agent
, with the radiologist reading an image without contrast agent and then a series of images after the contrast agent is injected to watch the uptake and the rate of the washout of the contrast agent, all of which may take experience.
Berlex Imaging of Montville, N.J., which manufactures the gadolinium-based contrast agent
Magnevist, said that as of Dec.
Matsuda et al., "Gadolinium-based contrast agent
accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy," Radiology, vol.
15 March 2011 - Bayer HealthCare Pharmaceuticals Inc said Monday that the US Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) Injection, a macrocyclic gadolinium-based contrast agent
(GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).
When patients with renal disease must receive a gadolinium-based contrast agent
, prompt dialysis following the MRI or MRA should be considered, the FDA statement said.
These are performed as multiple breath-hold sequences before and at timed intervals after IV bolus injection of a gadolinium-based contrast agent
. Reproducible diaphragmatic excursion during breath-holds allows for more accurate computer-processed image subtraction and better visual appreciation of the degree of lesion enhancement.